Cutaneous Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma, not otherwise specified: A systematic review and comparative analysis with Epstein-Barr Virus-negative, leg type
Description
Supplement 1. PRISMA flow diagram of literature search and study selection. EBV+ DLBCL, NOS, Epstein-Barr Virus-positive diffuse large B-cell lymphoma, not otherwise specified; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Supplement 2. Histopathological features of cutaneous Epstein-Barr Virus-positive diffuse large B-cell lymphoma, not otherwise specified. (A) Pleomorphic atypical large cells in a background rich in reactive cells such as lymphohistiocytes and plasma cells (hematoxylin and eosin, x200). (B) Monotonous sheets of immunoblast-like large cells (hematoxylin and eosin, x200). Atypical large lymphoid cells of cutaneous Epstein-Barr Virus-positive diffuse large B-cell lymphoma, not otherwise specified highlighted by (C) MUM-1 (x200), (D) BCL-2 (x200), and (E) CD30 (x200); Epstein-Barr Virus infection detected by (F) positive Epstein-Barr encoding region in situ hybridization (x200). Supplement 3. Survival analysis of cutaneous Epstein-Barr Virus-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS). (A) Difference in overall survival between primary cutaneous EBV+ DLBCL, NOS and primary cutaneous Epstein-Barr Virus-negative diffuse large B-cell lymphoma, leg type (EBV- DLBCL, leg type). (B) Comparison in survival between primary cutaneous EBV+ DLBCL, NOS and concurrent cutaneous and extracutaneous EBV+ DLBCL, NOS.